These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 33181320)

  • 21. Integrated hepatic single-cell RNA sequencing and untargeted metabolomics reveals the immune and metabolic modulation of Qing-Fei-Pai-Du decoction in mice with coronavirus-induced pneumonia.
    Tian S; Zheng N; Zu X; Wu G; Zhong J; Zhang J; Sheng L; Liu W; Wang C; Ge G; Han J; Zhao J; Li H; Zhang W
    Phytomedicine; 2022 Mar; 97():153922. PubMed ID: 35032732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical study on the treatment of Qingfei Paidu Granules combined with nondrug therapy for asymptomatic patients with novel coronavirus.
    Ling L; Xu Z; Yin F; Zhang Y; Sun Y
    Medicine (Baltimore); 2024 May; 103(19):e38016. PubMed ID: 38728524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming.
    Chen J; Wang YK; Gao Y; Hu LS; Yang JW; Wang JR; Sun WJ; Liang ZQ; Cao YM; Cao YB
    Biomed Pharmacother; 2020 Sep; 129():110281. PubMed ID: 32554251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qingfei Paidu Decoction for COVID-19: A Bibliometric Analysis.
    Liu SH; Ma Y; Shi NN; Tong L; Zhang L; Chen RB; Fan YP; Ji XY; Ge YW; Zhang HM; Wang YP; Wang YY
    Biomed Environ Sci; 2021 Sep; 34(9):755-760. PubMed ID: 34530968
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and Safety of Qingfei Paidu Decoction for Treating COVID-19: A Systematic Review and Meta-Analysis.
    Wang Q; Zhu H; Li M; Liu Y; Lai H; Yang Q; Cao X; Ge L
    Front Pharmacol; 2021; 12():688857. PubMed ID: 34456720
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
    Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
    Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
    Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
    Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tissue distribution of Qingfei Paidu Decoction based on HPLC-MS/MS].
    Zhang Y; Zhao HY; Yang LX; Zhou YY; Bian BL; Wu HK; Zhu HY; Si N; Lin PF; Wang L; Wang HJ
    Zhongguo Zhong Yao Za Zhi; 2023 Jun; 48(11):3074-3085. PubMed ID: 37381966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of Qingfei Paidu decoction combined with antiviral drugs in the treatment of corona virus disease 2019: A protocol for systematic review and meta analysis.
    Gao K; Song YP; Chen H; Zhao LT; Ma L
    Medicine (Baltimore); 2020 May; 99(22):e20489. PubMed ID: 32481460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Qingfei Paidu Granules combined with non-drug traditional Chinese medicine therapy in the treatment of patients with asymptomatic coronavirus disease: A retrospective study.
    Ling L; Wang X; Zhang Y; Yin F; Zhang Z; Lyu X
    Medicine (Baltimore); 2023 Nov; 102(46):e34868. PubMed ID: 37986280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Identification and attribution of chemical constituents of Qingfei Paidu Decoction based on UHPLC-LTQ-Orbitrap-MS technology].
    Zhou YY; Gao WY; Gu XR; Chen ZQ; Zhao HY; Bian BL; Yang LX; Si N; Wang HJ; Tan Y
    Zhongguo Zhong Yao Za Zhi; 2020 Jul; 45(13):3035-3044. PubMed ID: 32726009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui, China.
    Zuo Y; Liu Y; Zhong Q; Zhang K; Xu Y; Wang Z
    J Med Virol; 2020 Nov; 92(11):2666-2674. PubMed ID: 32492211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study.
    Qi L; Yang Y; Jiang D; Tu C; Wan L; Chen X; Li Z
    Int J Infect Dis; 2020 Jul; 96():531-537. PubMed ID: 32425636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort study.
    Zhang X; Xue Y; Chen X; Wu JM; Su ZJ; Sun M; Liu LJ; Zhang YB; Zhang YL; Xu GH; Shi MY; Song XM; Lu YF; Chen XR; Zhang W; Chen Q
    J Integr Med; 2021 Jan; 19(1):36-41. PubMed ID: 33069626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].
    Zhang YS; Cong WH; Zhang JJ; Guo FF; Li HM
    Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1263-1271. PubMed ID: 32281335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2.
    Xu X; Xia J; Zhao S; Wang Q; Ge G; Xu F; Liu X; Zhang W; Yang Y
    FASEB J; 2021 Sep; 35(9):e21870. PubMed ID: 34436790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection effects of mice liver and lung injury induced by coronavirus infection of Qingfei Paidu decoction involve inhibition of the NLRP3 signaling pathway.
    Huang W; Chen X; Yin M; Li J; Luo M; Ai Y; Xie L; Li W; Liu Y; Xie X; Chen Y; Zhang X; He J
    J Ethnopharmacol; 2024 Mar; 321():117512. PubMed ID: 38040130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
    Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
    Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study.
    Zeng QL; Li GM; Ji F; Ma SH; Zhang GF; Xu JH; Lin WB; Xu GH; Zhang GQ; Li GT; Cui GL; Liu N; Zeng FJ; Ai ZG; Xu GF; Liu N; Liang J; Zhang MM; Li C; Zhang ZH; Wang ZS; Li Z; Yu ZJ
    Transbound Emerg Dis; 2020 Nov; 67(6):2971-2982. PubMed ID: 32531138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.